EP2710027A1 - Auf bombesinrezeptor gerichtetes peptid mit einer 1, 2, 3-triazolgruppe im rückgrat zur herstellung von in-vivo-diagnostika und therapeutika - Google Patents

Auf bombesinrezeptor gerichtetes peptid mit einer 1, 2, 3-triazolgruppe im rückgrat zur herstellung von in-vivo-diagnostika und therapeutika

Info

Publication number
EP2710027A1
EP2710027A1 EP12724303.8A EP12724303A EP2710027A1 EP 2710027 A1 EP2710027 A1 EP 2710027A1 EP 12724303 A EP12724303 A EP 12724303A EP 2710027 A1 EP2710027 A1 EP 2710027A1
Authority
EP
European Patent Office
Prior art keywords
peptide
peptides
variant according
peptide variant
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12724303.8A
Other languages
English (en)
French (fr)
Inventor
Thomas MINDT
Ibai VALVERDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsspital Basel USB
Original Assignee
Universitaetsspital Basel USB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsspital Basel USB filed Critical Universitaetsspital Basel USB
Priority to EP12724303.8A priority Critical patent/EP2710027A1/de
Publication of EP2710027A1 publication Critical patent/EP2710027A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to stabilized peptides wherein carboxamide functions are replaced by triazoles, corresponding stabilized peptides conjugated with a radioactive or nonradioactive reporter probe and/or therapeutic agent, and the use thereof in diagnosis and therapy.
  • Regulatory peptides represent a class of high affinity ligands for GPC receptors over-expressed by cancer cells. In combination with reporter probes, they display ideal characteristics for the development of molecular imaging
  • the invention relates to linear stabilized peptides, wherein one, two or more carboxamide functional groups located in the backbone are replaced by a 1 ,4- or 1 ,5-substituted 1 ,2,3- triazole, in particular, wherein the replaced carboxamide functional groups are at or near amide bond cleavage sites.
  • These peptides have similar properties as the peptides from which they are derived, but show increased serum stability. Examples of peptides considered are receptor targeting peptides, such as regulatory peptides.
  • the invention also relates to variants and fragments of the mentioned peptides, for example peptides wherein further carboxamide functional group are replaced by suitable carboxamide mimics, multimers, peptides carrying suitable substituents, such as solubilizing substituents and chelators, optionally connected through spacers, and peptides carrying non-metallic radioisotopes, non-metallic and metallic dyes,
  • paramagnetic metals or radioactive metals.
  • the invention further relates to the use of the linear stabilized peptides and variants carrying non-metallic radioisotopes, non-metallic and metallic dyes, paramagnetic metals, or radioactive metals in diagnosis and therapy, in particular diagnosis of cancer and therapy of cancer and/or reduction of side effects in cancer treatment.
  • % percent of internalized radiolabeled peptide
  • t(min) time (in minutes)
  • % ID/g Percent of injected dose per gram of tissue
  • the invention relates to linear stabilized peptides wherein one, two or more, e.g. three, four or five, carboxamide functional groups located in the backbone are replaced by a 1 ,4- or 1 ,5-substituted 1 ,2,3-triazole.
  • the invention relates to such peptides wherein one, two or more carboxamide functional groups at or near amide bond cleavage sites are replaced by 1 ,4- or 1 ,5-substituted 1 ,2,3-triazole.
  • the invention relates to such peptides, which target receptors, for example cell membrane receptors of cancer cells, in particular, regulatory peptides.
  • a "naturally occurring amino acid” is one of the 22 oarmino acids that are genetically encoded and thus usually found in natural proteins. These are Ala, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, lie, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Pyl (pyrrolysine) and Sec (selenocysteine).
  • a "non-proteinogenic amino acid” is an amino acid not usually present in natural proteins, i.e. an amino acid different from the mentioned 22 oarmino acids above.
  • amide bond cleavage site as understood in the present invention is an amide bond between two amino acids of a peptide's amino acid sequence, or of a peptide fragment's amino acid sequence, respectively, which is prone to enzymatic or hydrolytic cleavage in vivo.
  • amide bond cleavage sites are those prone to cleavage by intra- and extracellular peptidases involved in the activation or inactivation of regulatory peptides.
  • Particular bonds are those prone to hydrolysis.
  • General examples of particular bonds of interest and their corresponding hydrolysing enzymes are shown in Table 1.
  • Table 1 Examples of particular bonds of interest and the corresponding enzymes responsible for the cleavage
  • Xaa means any amino acid
  • Preferred are the known bonds of regulatory and signalling peptides that undergo hydrolysis in vivo. Examples of preferred bonds of interest and their hydrolysing enzymes are shown in Table 2. Table 2: Examples of preferred bonds of interest and corresponding enzymes responsible for the proteolysis
  • a carboxamide functional group "near" an amide bond cleavage site as understood in the present invention means a carboxamide functional group adjacent to any of the cleavage site depicted above.
  • Regulatory peptides as understood in the present invention are peptides which physiologically play a modulatory role in the human body in regions as varied as the brain; gastrointestinal tract; and endocrine, vascular, or lymphoid systems. They mediate their functions through high-affinity, specific, usually G-protein-coupled (GPC) receptors. In many incidences, the corresponding receptors have been shown to be massively overexpressed in numerous cancers.
  • GPC G-protein-coupled
  • regulatory peptides considered are bombesin, gastrins and mini gastrins, exendins (exendin-3 and exendin-4), neuropeptide-Y, neurotensin, substance P, alpha- MSH peptides (CCMSH), vasoactive intestinal peptides (VIP), CXCR4 peptides, gonadotropin releasing hormone (GnHR) peptides, glucagon like peptide-1 (GLP-1 ) and linear peptidic variants and fragments of such peptides.
  • non-regulatory peptides considered are non-cyclic RGD peptides.
  • the invention relates to both, peptidic agonists and antagonists.
  • Peptide agonists stimulate the function of the targeted receptor such as release of intracellular messenger substances (e.g. Ca 2+ mobilization) or triggering the internalization of the receptor-ligand complex.
  • Peptide antagonists do not stimulate the function of the targeted receptor.
  • Antagonists bind to the receptor with similar affinity as agonists and can therefore block the activity of the receptor.
  • Preferred are peptides which target cell membrane receptors (e.g., GPC-receptors) with high affinity (Kd in the nanomolar range).
  • Receptors (r) of interest are GRP-r, CCK 2 -r, CCK r, GLP-1 -r, Y1 -r, NT1 -r, NK-1 -r, MC1 -r, VPAC-1 -r, GnRH-r, chemokine-4-r, and intergrins (e.g.
  • peptides which target cell membrane receptors that are overexpressed by tumour cells involved in, for example, prostate, breast, lung, medullary thyroid and ovarian cancer, and insulinomas, glioblastomas, neuroblastomas, adenocarcinomas, and (neuro)endocrine tumours.
  • "Fragments” as understood in the present invention are peptides, wherein one, two or more, for example up to 25 amino acids, are removed from either one or both ends of the peptide or within the amino acid sequence and which retain their regulatory peptide properties or high affinity to the corresponding receptor, respectively.
  • fragments with receptor affinities, cell binding, cell internalization and pharmacokinetic characteristics comparable or improved to those of the peptides from which they are formed include but are not limited to the binding sequence of bombesin (amino acids 7-14), exendin-4 (amino acids 9-39), neurotensin (amino acids 8- 13), and gastrin (amino acids 1 -14; minigastrin), and GLP-1 (amino acids 7-37).
  • Alkyl groups considered are CrC 4 -alkyl, in particular methyl, and benzyl.
  • Acyl groups considered are CrC 4 - alkylcarbonyl, in particular acetyl, formyl, tert-butoxycarbonyl and benzyloxycarbonyl.
  • variants which retain their receptor targeting peptide properties in particular the receptor affinities, cell binding properties, and cell internalization characteristics of the peptide from which the variant is derived.
  • variants which retain their receptor targeting peptide properties display improved stabilities and pharmacokinetic profiles in comparison to the native peptide or fragments thereof as defined above. Improved pharmacokinetic profiles means favourable rate and route of excretion (e.g. fast renal clearance) and minimized unspecific uptake in non-targeted tissue.
  • Examples of such peptides include the above described regulatory peptides, fragments thereof and RGD peptides.
  • pharmacological modifier e.g. solubilizing substituent, at the N- or C-terminal.
  • “solubilizing substituent” as understood in the present invention is a pharmacological modifiers which increases the hydrophilicity and hence water solubility of the peptide.
  • Such substituents further modify the pharmacokinetics and the pharmacodynamics of the peptide, to which they are attached.
  • Preferred solubilizing substituents are polyethylene glycols, carbohydrates, and poly-sulfonated or poly-hydroxylated linear or cyclic aliphatic or unsaturated hydrocarbons. Most preferred solubilizing substituent is polyethylene glycol, for example a polyoxyethylene group of 2 to 2000 polyoxyethylene units.
  • Other highly preferred solubilizing agents are mono- or poly-carbohydrates, i.e. one to ten carbohydrates linked to the peptide via C-C, C-0 or C-N bonds.
  • Chelator groups considered are multidentate, cyclic or acyclic structures with two to fifteen metal coordination sites, in particular coordination sites represented by heteroatoms (nitrogen, oxygen, sulfur, phosphorus) and the corresponding functional groups, e.g.
  • Saturated and unsaturated heterocycles considered are, e.g., pyrroline, pyrrolidine, oxazoline, oxazolidine, thiazoline, thiazolidine, piperidine, morpholine, piperazine, dioxane, 1 ,2,3-triazole, di- and tetrahydrofuran and di- and tetrahydropyran, and optionally substituted benzo fused derivatives of such monocyclic heterocyclyl, for example indoline and benzoxazolidine, all optionally substituted, for example by amine, hydroxy, oxo, thiono, carboxy, sulfuric or sulfonic acid, or phosphorous, phosphoric or phosphonic acid functions.
  • Aromatic heterocycles considered are, e.g., pyrrol, thiophene, furane, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and benzo fused derivatives of such monocyclic heteroaryl groups, such as indole, benzimidazole, benzofuran, quinoline, or isoquinoline, all optionally substituted, for example by amine, hydroxy, carboxy, sulfonic acid or phosphonic acid functions.
  • multidentate, cyclic or acyclic chelators which are known to form in vivo stable complexes with radioactive or non-radioactive metals, in particular with those metals listed below.
  • Particularly preferred are cyclic or acyclic derivatives of polyamines which are covalently derivatized via either a C-C, C-O, or C-N bond with aliphatic or aromatic carboxylates, amines, thiols, and phosphonates.
  • cyclic or acyclic chelators include those derived from polyamines such as cyclam (1 ,4,8,1 1 -tetraazacyclo- tetradecane), cyclen (1 ,4,7,10-tetraazacyclododecane) and crossbridged (CB) versions thereof (e.g.
  • chelators derived from the above described cyclic frameworks include, but are not limited to, DOTA (2,2',2",2"'-(1 ,4,7,10-tetraazacyclododecane- 1 ,4,7,10-tetrayl)tetraacetic acid), NOTA (2,2',2"-(1 ,4,7-triazacyclononane-1 ,4,7-triyl)- triacetic acid), TETA (1 ,4,8,1 1 -tetraazacyclo-dodecane-1 ,4,8,1 1 -tetraacetic acid), including cross-bridged versions thereof (e.g.
  • chelators derived from the above described acyclic frameworks include, but are not limited to, DTPA (2,2',2",2"'-((((carboxymethyl)azanediyl)- bis(ethane-2,1 -diyl))bis(azanetriyl))tetraacetic acid) and desferrioxamine (DFO, or desferal; /V'- ⁇ 5-[acetyl(hydroxy)amino]pentyl ⁇ -/V-[5-( ⁇ 4-[(5-aminopentyl)(hydroxy)amino]-4- oxobutanoyl ⁇ amino)pentyl]-/V-hydroxysuccinamide).
  • Most preferred chelators for Tc-99m include, but are not limited to known chelators for Tc-99m in its oxidation state +1 , +4 or +5, for example, MAG 3 , PAMA, and 1 ,2,3-triazole- containing mono-, di- and tri-dentate chelators.
  • the mentioned chelator groups may be directly bound to the N- or C-terminus of the peptide, or connected through a spacer.
  • Spacers considered are optionally substituted linear or cyclic aliphatic or aromatic hydrocarbons or saturated, unsaturated and aromatic heterocycles of 1 to 30 carbon atoms further comprising hydroxy, thio, amino or carboxy functional groups for connection with the peptide and/or the chelator, multiple neutral or charged amino acids, for example 1 to 10 amino acids selected from the natural 20 amino acids, or polyethylene glycol (PEG) comprising 2 to 20 polyethylene units, and
  • Linear aliphatic hydrocarbons may also be partially unsaturated, for example as in natural fatty acids.
  • Cyclic aliphatic hydrocarbons are, e.g., cyclopentane or cylcohexane.
  • Aromatic hydrocarbons considered are, in particular benzene, being further substituted in 1 ,2-, 1 ,3- or 1 ,4-position, naphthalene, or anthracene.
  • Optional substituents are, for example, methyl, ethyl, benzyl, hydroxymethyl, methoxymethyl, aminomethyl, hydroxy, methoxy, ethoxy, amino, methyl- or dimethylamino, carboxy, aminocarbonyl, methoxycarbonyl, ethoxycarbonyl, and in case of aliphatic hydrocarbon also oxo.
  • Saturated, unsaturated and aromatic heterocycles considered are those mentioned above.
  • a particular heterocycle considered is succinimido.
  • the peptides or the chelators these may be combined through a carboxamide function, a disulfide bridge, an ether, an amino or a thioether function.
  • a particular peptide variant according to the invention is compound of the formula
  • A is a chelator
  • C is a linear stabilized receptor targeting peptide wherein one, two or more carboxamide functional groups located in the backbone are replaced by a 1 ,4- or 1 ,5-substituted 1 ,2,3- triazole.
  • Chelator A in the mentioned formula has the meaning of a chelator as defined above.
  • Spacer B in the mentioned formula may be a "solubilizing substituent" as defined above, being further connected to the chelator A.
  • Preferred spacers B having the properties of a solubilizing substituent are polyethylene glycols, carbohydrates, and poly-sulfonated or poly-hydroxylated linear or cyclic aliphatic or unsaturated hydrocarbons, in particular a polyoxyethylene group of 2 to 2000, e.g. 2 to 20 polyoxyethylene units.
  • Spacer B is an optionally substituted linear or cyclic aliphatic or aromatic hydrocarbon or saturated, unsaturated and aromatic heterocycle of 1 to 30 carbon atoms further comprising hydroxy, thio, amino or carboxy functional groups for connection with the linear stabilized receptor targeting peptide C and/or the chelator A.
  • Such a spacer B may be a short peptidic stretch of neutral or charged amino acids, for example of 1 to 10 amino acids selected from the natural 20 amino acids, or combinations of amino acids with polyethylene glycol (PEG) comprising 2 to 20 polyethylene units.
  • spacers B consisting of one to four charged or uncharged amino acids, e.g., a combination of Gly, Ala, pAla, Pro, Phe, Ser, Arg, Asp, Asn, Glu, Gin, Leu, Lys, Met, Trp, Tyr, and other aliphatic amino acid, e.g. linear aminoalkanoic acid (C 3 -C 6 ), disubstituted carbocycles, e.g. cyclohexyl mono-, di- or tri-amine, disubstituted
  • amino acids e.g., a combination of Gly, Ala, pAla, Pro, Phe, Ser, Arg, Asp, Asn, Glu, Gin, Leu, Lys, Met, Trp, Tyr, and other aliphatic amino acid, e.g. linear aminoalkanoic acid (C 3 -C 6 ), disubstituted carbocycles, e.g. cyclohexyl
  • heterocycles e.g., morpholine or tetrahydrofuran, disubstituted aromatic carbocycles based on benzene or anthracene, disubstituted aromatic heterocycles, e.g. thiazole, triazole, imidazole or pyridine, succinimido, or polyethylene glycol.
  • m is an integer from 0 to 6, meaning that the spacer may have up to 6 repetitive units.
  • x is an integer from 1 to 6, meaning that the linear stabilized receptor targeting peptide C may carry one, two, three, four, five or six chelators A connected through (optionally repetitive) spacer B.
  • these groups may also be coupled via a side chain function of a natural or non- natural amino acid within the amino acid sequence of the peptide C.
  • Preferred amino acids with side chain functionalization for coupling with chelators are those bearing one of the following functional groups or, alternatively, those into which one of the following functional groups had been introduced: amine, thiol, carboxylate, halogen, alkyne, alkene, alcohol, aldehyde, azide, hydrazine, N-oxime, phosphate, thiol, and disulfide.
  • a particular peptide variant of the formula [A-(B) m ] x -C is the compound wherein
  • C is a bombesin receptor targeting peptide of the formula
  • Xaa 6 is the D-isomer of a naturally occurring amino acid or a non-proteinogenic a-D-amino acid with an aromatic side chain, e.g. phenyl, substituted phenyl such as p-hydroxyphenyl, biphenylyl, naphthyl, pyridyl, indolyl, imidazolyl, p-chlorophenyl, p-bromophenyl, thienyl, or thiazolyl, such as an amino acid selected from D-Phe, D-Tyr, D-Trp, D-Thi (D-thienyl- alanine), D-1 Nal (3-(1 -naphthyl)alanine), D-2Nal (3-(2-naphthyl)alanine), or is missing; 1 1 has the formula
  • n 1 or 2;
  • Xaa 12 is any amino acid, preferably Leu, Phe, or statin or a statin variant of the formula
  • Xaa 13 is a naturally occurring or a non-proteinogenic a-amino acid with an aliphatic side- chain selected from Leu, cyclopentylalanine, Cha (cyclohexylalanine), i-BuGly, i-BuAla, Met, Nle, and / ' -BuGly; and
  • Z is NH or O.
  • the superscripts 7 to 10 in the amino acids correspond to amino acids in bombesin, i.e the amino acids -Gln 7 -Trp 8 -Ala 9 -Val 10 - are those of bombesin, but other amino acids of bombesin are missing (1 -5, or 1 -6 if Xaa 6 is missing) or are replaced by related amino acids.
  • the compound is a peptide with a free carboxyl function at the C terminal end. If Z is NH, the compound is a peptide with a carboxamide function at the C terminal end.
  • Xaa 6 is D-Phe or D-Tyr. In an alternative preferred mode, Xaa 6 is missing.
  • a particularly preferred peptide C is
  • R 2 is isopropyl or phenyl.
  • a further particular peptide variant of the formula [A-(B) m ] x -C is the compound wherein C is a bombesin receptor agonist of the formula
  • Z is O or NH, preferably NH.
  • Multimers are compounds consisting of multiple numbers of the stabilized peptides connected through a central, multifunctional molecule which combines the peptides in a comb-like, tree-like or star-like shape.
  • Examples of such central, multifunctional molecules are aliphatic or aromatic hydrocarbons with multiple functional groups such as carboxylates or amines, e.g., compounds derived from tris(hydroxymethyl)methylamine, tris(hydroxy- methyl)methanol, ethylene diamine tetraacetic acid, or diethylene amine pentaacetic acid.
  • Polymers can be homopolymers, copolymers, and block copolymers. Examples include but are not limited to crosslinked or not crosslinked polyacrylates, polymethacrylates, polyvinyls, poly- ethyleneglycols, polypropyleneglycols, polyacrylamides, polymethacrylamides, poly- amides, polyesters, polycarbonates, polyurethanes, polyolefines, polyhalogenolefines, polyethers, polysaccharides, and polyethylenecarbonat.es.
  • Particular multimers considered are dimers, trimers and tetramers of the triazole-stabilized peptides, optionally conjugated with a radioactive or non-radioactive reporter probe for imaging applications as described below, and conjugates of the multimers with therapeutic radioisotopes, as described below, and combinations thereof.
  • receptor targeting peptide 1 ,2,3-triazoles are replacing one or more carboxamide functional groups at or near amide bond cleavage sites the resulting peptide is stabilized against peptide cleavage without significantly changing its physico-chemical properties (e.g. Log P), high affinity to the corresponding GPC receptors (Kd) and cell binding and internalization behaviour.
  • Log P physico-chemical properties
  • Kd GPC receptors
  • the invention further relates to linear stabilized peptides, wherein one or more
  • carboxamide functional groups are replaced by a 1 ,4- or 1 ,5-substituted 1 ,2,3-triazole described herein, carrying non-metallic radioisotopes, non-metallic and metallic dyes, paramagnetic metals, or radioactive metals.
  • Non-metallic radioisotopes considered are C-1 1 , F-18, Br-75, Br-76, Br-77, Br-80, 1-123, I- 125, 1-131 , and At-21 1 .
  • the non-metallic radioisotopes may be conjugated covalently to either terminus of the peptide, functional groups of amino acid side chains, be part of a linear stabilized peptide as an additional substituent, e.g. in an amino acid phenylalanine or tyrosine carrying fluorine, bromine or iodine, or as an additional substituent carboxy or methyl, or as a replacement of any regular carbon atom in the peptide by C-1 1.
  • prosthetic groups e.g. SFB, FBA, FPA, FPyMe for F-18, or methyl iodide for C-1 1
  • isotope-exchange technologies can be used to introduce non-metallic radioisotopes.
  • Particular non-metallic radioisotopes considered are C-1 1 , F-18, 1-125 and 1-131 .
  • Non-metallic radioisotopes are useful in peptides as positron emission tomography (PET) probes or as single-photon emission computed tomography (SPECT) probes, with the exception of 1-131 , useful in therapeutic applications.
  • Further peptides considered as PET and SPECT probes are those carrying metallic radioisotopes (see below).
  • Non-metallic and metallic dyes considered are organic molecules, e.g., commercial Alexa fluor dyes, fluorescein, rhodamine, or Cy5.5, complexes of transition metals, e.g.
  • Organic dyes and chelating systems will be coupled to the peptides as described above for chelators. Conjugation of the peptides with quantum dots is done by procedures known to those skilled in the art. These peptides carrying dyes are useful as optical imaging probes. Paramagnetic metals considered are Gd, Fe, Mn, preferably Gd. The metals are attached to the peptides as will be described below. These peptides are useful as magnetic resonance imaging (MRI) probes.
  • MRI magnetic resonance imaging
  • Metallic radioisotopes are, for example, Tc-99m, ln-1 1 1 , Ga-67, Ga-68, Lu-177, Cu-64, and Zr-89, useful in imaging, and Re-186/188, Bi-213, Y- 90, Cu-67, Lu-177, Tb-161 , Tc-99m, and ln-1 1 1 for therapeutic applications.
  • the metallic radioisotopes (and the paramagnetic metals mentioned above) are attached to the peptides of the invention through chelators as listed above, directly connected to the peptides or through a spacer.
  • the chelators and spacers considered are those described above.
  • Preferred radioisotopes for diagnostic applications are Tc- 99m, ln-1 1 1 , Ga-68, Ga-67, and F-18.
  • Preferred radioisotopes for therapeutic applications are Lu-177, Y-90, Tb-161 , and Re-188.
  • Tc-99m and ln-1 1 1 are not only useful for imaging, but also have therapeutic applications as Auger electron emitters.
  • radioisotopes are Tc-99m, Ga-68, ln-1 1 1 , Cu-64, F-18, Y-90, Lu-177 and Re-188/186.
  • the invention relates to a radioconjugate
  • the invention further relates to the use of the linear stabilized peptides carrying non- metallic radioisotopes, non-metallic and metallic dyes, paramagnetic metals, and/or radioactive metals described herein in diagnosis and therapy, in particular in diagnosis and therapy in the field of oncology.
  • triazole-stabilized peptides are also of clinical use for the management of cancer without the combination with radioactive isotopes.
  • regulatory peptides and derivatives thereof can be of clinical relevance for reducing not only the progression of the disease (tumor growth and formation of metastases), but also provide the means for a remedy for undesirable side effects associated with the disease.
  • Linear stabilized peptides wherein one, two or three carboxamide functional groups are replaced by a 1 ,4- or 1 ,5-substituted 1 ,2,3-triazole, are preferably manufactured by cycloaddition reactions combining properly substituted azides and alkynes.
  • Azide and alkyne building blocks are prepared according to literature procedures.
  • a-Azido amino derivatives are prepared by the reaction of commercial amino acids with either azido triflate (J.T. Lundquist and J.C. Pelletier, Org. Lett. 2001 , 3, 781 -783) or imidazole- 1 -sulfonyl azide hydrochloride (E.D. Goddard-Borger and R.V. Stick, Org. Lett. 2007, 9, 3797-3800).
  • Corresponding alkynes are prepared by either the Corey-Fuchs or the Seyferth-Gilbert homologation protocol (E. J. Corey and P. L. Fuchs, Tetrahedron Letters, 1972, 3769; J. C. Gilbert, U. Weerasooriya, Journal of Organic Chemistry, 1982, 47, 1837).
  • Reaction of alkyne and azide derivatives to form 1 ,2,3-triazoles is accomplished by Cu(l)- or Ru(l)-catalysis either in solution or on solid support (M. Meldal and C.W. Torn0e,
  • Peptide synthesis and conjugation with various spacers and/or chelators is performed by solid phase synthesis. Individual coupling steps (formation of amide bonds or triazole linkages) can also be carried out individually in solution.
  • the Weinreb amide (0.1 mmol) was dissolved in 1 mL of anhydrous CH 2 CI 2 , and the solution cooled to -78°C.
  • DIBAL-H (0.3 mmol, 300 ⁇ _, 1 M solution in CH 2 CI 2 ) was added dropwise and the mixture was allowed to stir at -78°C until completion of the reduction (TLC monitor).
  • the excess of DIBAL-H was quenched with 1 mL of anhydrous methanol, and the reaction mixture allowed to warm up to 0°C.
  • Example 2 g-Azide analogue of n-leucine, (S)-2-azidohexanoic acid
  • Example 4 g-Azide analogue of histidine, (S)-2-azido-3-(1 -trityl-1 H-imidazol-4-vQ- propanoic acid
  • the Weinreb amide of leucine was obtained in quantitative yields as a colourless oil according to procedure 5.
  • Spectrometric data of the compound were found to be identical to literature data (M. Rodriguez, J. P. Brown, R. Magous, B. Castro, and J. Martinez, Int. J. Pept. Protein Res. 1986, 27, 293-299).
  • Boc-protected alkynyl analogue of leucine was obtained according to general procedure 6. After the aqueous work-up, the residue was purified by silica gel flash chromatography (n-hexane/EtOAc 95:5 to 9:1 ) to furnish the desired compound in 72% yield.
  • Spectrometric data of the compound were found to be identical to literature data (E. Ko and K. Burgess, Org. Lett. 201 1 , 13, 980-983).
  • the alkynyl analogue of alanine was obtained following the procedure 6 described above for example 5.
  • the Boc-protected intermediate was previously described and was found to have identical spectrometric data to those described in the literature (Reginato, G.; Mordini, A.; Messina, F.; Degl'lnnocenti, A.; Poli Giovanni Tetrahedron 1996, 5, 10985- 10996).
  • Example 7 Alkynyl analogue of glycine, (9H-fluoren-9-yl)methyl prop-2-yn-1 -ylcarbamate
  • the alkynyl analogue of the amino acid glycine corresponds to commercial propargyl- amine, the Fmoc derivatives of which was prepared by the following procedure: To an ice- cooled solution of propargylamine (1 10 mg, 2 mmol, 1 equiv.) and / ' -Pr 2 NEt (383 ⁇ _, 2.2 mmol, 2.2 equiv.) in CH 2 CI 2 (20 mL) was added Fmoc-OSu (741 mg, 2.2 mmol, 1 .1 equiv.) in portions and the mixture was allowed to stir 1 h at RT.
  • the peptide resin was then cleaved and deprotected by a standard 3 h-treatment with a mixture of TFA/H 2 0/TIS/PhOH (87.5:5:2.5:5), and the peptide was precipitated with ice-cold diethyl ether, recovered by centrifugation and washed twice with cold diethyl ether. The precipitate was purified by preparative HPLC
  • the amino acids from 13 to 14 were coupled by automated solid phase on a commercial Rink Amide MBHA LL resin (100-200 mesh) (0.03 mmol) using general procedure 1.
  • the a-azido-His(Trt)-OH was coupled manually on the resin by general procedure 2.
  • the coupling was followed by solid phase CuAAC with Fmoc-propargyl amine by general procedure 3.
  • Residues 7 to 10, the spacer and the chelator DOTA-tri(ieri-butyl) ester (1 ,4,7-tris(ie f-butoxycarbonylmethyl)-1 ,4,7,10-tetraazacyclododecane-10-acetic acid) were subsequently coupled manually following general procedure 2.
  • the peptide resin was then cleaved and deprotected by a standard 3 h treatment with a mixture of TFA/H 2 0/TIS/PhOH (87.5:5:2.5:5), and the peptide was precipitated with ice-cold diethyl ether, recovered by centrifugation and washed twice with cold diethyl ether.
  • the precipitate was purified by preparative HPLC (25-27% CH 3 CN in 12 min; rest 0.1 % aq. TFA; flow rate: 8 mL/min) to obtain the peptide in 64% yield (purity according to HPLC >95%).
  • the amino acids from 1 1 to 14 were coupled by automated solid phase on a commercial Rink Amide MBHA LL resin (100-200 mesh) (0.03 mmol) using general procedure 1.
  • the oazido-Val-OH was coupled manually on the resin by general procedure 2.
  • the coupling was followed by solid phase CuAAC with Fmoc-protected alkynyl analogue of alanine by general procedure 3.
  • Residues 7 to 8 the spacer and the chelator DOTA-tri(ieri-butyl) ester (1 ,4,7-tris(ie f-butoxycarbonylmethyl)-1 ,4,7,10-tetraazacyclododecane-10-acetic acid) were subsequently coupled manually following general procedure 2.
  • the peptide resin was then cleaved and deprotected by a standard 3 h treatment with a mixture of TFA/H 2 0/TIS/PhOH (87.5:5:2.5:5), and the peptide was precipitated with ice-cold diethyl ether, recovered by centrifugation and washed twice with cold diethyl ether.
  • the precipitate was purified by preparative HPLC (25-27% CH 3 CN in 12 min; rest 0.1 % aq. TFA; flow rate: 8 mL/min) to obtain the peptide in 20% yield (purity according to HPLC >95%).
  • Example 1 Radiolabelling with 177 Lu
  • Radiolabelling with 177 Lu was accomplished by reacting 20 ⁇ g of peptides (approx. 12.8 nmol) with -37 MBq 177 LuCI 3 in 300 ⁇ 0.4 M NH 4 OAc (pH 5.0) in a pre-lubricated
  • the internalization was stopped by removal of the medium followed by washing the cells (2x) with ice-cold solution composed of 0.01 M PBS buffer pH 7.4. Cells were then treated with glycine buffer (0.05 M, pH 2.8) twice for 5 min at 4°C to determine the cell surface bound fraction. Finally, cells were detached and lysed from the plates by incubation with 1 M NaOH aqueous solution for 10 min at 37°C.
  • Radioactivity of all solutions was measured in a gamma counter. The percentage of added activity per million cells (% of total) was calculated and decay-corrected for each time point. Both peptides exhibited identical in vitro behavior resulting in approx. 25% internalized radiopeptide within 1 -2 h ( Figure 1 ).
  • Example 13 Saturation binding experiments for determination of receptor affinities PC-3 cells at confluence were placed in 6-well plates ( ⁇ 10 6 cells/well). To the cells was added at different concentrations the 177 Lu-radiolabeled peptides (1 , 5, 10, 50, 100, 500, 1000 nM) corresponding to a final concentration of peptide per well of 0.1 to 100 nM. The different plates were then incubated for 2 h at 4°C (final volume, 1 mL/well). After two washing steps with cold 0.01 M PBS pH 7.4, the cells were detached from the plates by incubation in 1 M NaOH aqueous solution for 10 min at 37°C. The radioactivity of solutions was measured in a gamma counter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP12724303.8A 2011-05-19 2012-05-18 Auf bombesinrezeptor gerichtetes peptid mit einer 1, 2, 3-triazolgruppe im rückgrat zur herstellung von in-vivo-diagnostika und therapeutika Withdrawn EP2710027A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12724303.8A EP2710027A1 (de) 2011-05-19 2012-05-18 Auf bombesinrezeptor gerichtetes peptid mit einer 1, 2, 3-triazolgruppe im rückgrat zur herstellung von in-vivo-diagnostika und therapeutika

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166815 2011-05-19
EP12724303.8A EP2710027A1 (de) 2011-05-19 2012-05-18 Auf bombesinrezeptor gerichtetes peptid mit einer 1, 2, 3-triazolgruppe im rückgrat zur herstellung von in-vivo-diagnostika und therapeutika
PCT/EP2012/059270 WO2012156511A1 (en) 2011-05-19 2012-05-18 Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents

Publications (1)

Publication Number Publication Date
EP2710027A1 true EP2710027A1 (de) 2014-03-26

Family

ID=46178524

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12724303.8A Withdrawn EP2710027A1 (de) 2011-05-19 2012-05-18 Auf bombesinrezeptor gerichtetes peptid mit einer 1, 2, 3-triazolgruppe im rückgrat zur herstellung von in-vivo-diagnostika und therapeutika

Country Status (2)

Country Link
EP (1) EP2710027A1 (de)
WO (1) WO2012156511A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3459559A1 (de) * 2017-09-21 2019-03-27 Paul Scherrer Institut Minigastrinderivate, insbesondere zur verwendung in positiver cck2-rezeptor-tumordiagnose und/oder -behandlung
EP3868394A1 (de) * 2020-02-20 2021-08-25 Paul Scherrer Institut Mono- und multi-triazolominigastrine für das targeting von cck2r-positiven neoplasien

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100900A1 (de) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin-analoge Peptid-antagonistische Konjugate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012156511A1 *

Also Published As

Publication number Publication date
WO2012156511A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
KR101734553B1 (ko) 봄베신 유사체 펩티드 길항제 접합체
Failla et al. Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
JP7026784B2 (ja) ミニガストリン誘導体、特にｃｃｋ２受容体陽性腫瘍の診断及び／又は治療において使用するためのミニガストリン誘導体
JP7502801B2 (ja) ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物
JP6979180B6 (ja) 診断及び治療のための、改善された薬物動態及びコレシストキニン－２受容体（ｃｃｋ２ｒ）への標的化
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
JP2025106360A (ja) 癌のイメージングおよび治療のための修飾されたｇｒｐｒアンタゴニストペプチド
WO2012156511A1 (en) Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
US20120178906A1 (en) Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
TW202241926A (zh) 用於診斷及治療之改良的膽囊收縮素-2受體(cck2r)標靶
WO2021165285A1 (en) Mono- and multi-triazolominigastrins for targeting of cck2r-positive neoplasms
TW202231655A (zh) 用於診斷及治療之改良的膽囊收縮素-2受體(cck2r)標靶
Floresta et al. RSC Medicinal Chemistry
EP4288117A1 (de) Verbessertes targeting des cholecystokinin-2-rezeptors (cck2r) für diagnose und therapie
HK1153760B (zh) 铃蟾肽类似肽拮抗物缀合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151201